We are live on ! Find out more
VIA

Vident Investment Advisory Portfolio holdings

AUM $2.9B
1-Year Est. Return 24.67%
This Fund
S&P 500
This Quarter Est. Return
+3.66%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$201M
Cap. Flow
+$179M
Cap. Flow %
14.8%
Top 10 Hldgs %
14.79%
Holding
464
New
45
Increased
341
Reduced
52
Closed
26

Top Buys

Rank Stock Value
1
ZBRA icon
Zebra Technologies
ZBRA
+$8.61M
2
OII icon
Oceaneering
OII
+$7.8M
3
PTC icon
PTC
PTC
+$7.55M
4
CGNX icon
Cognex
CGNX
+$6.25M
5
HOLI
Hollsys Automation Technologies INTERNATIONAL, LTD. COMMON (British Virgin Island)
HOLI
+$6.06M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.6M
2
ESLT icon
Elbit Systems
ESLT
+$4.36M
3
MBLY
Mobileye N.V.
MBLY
+$4.01M
4
BAC icon
Bank of America
BAC
+$2.75M
5
ANDV
Andeavor
ANDV
+$2.53M

Sector Composition

Rank Sector Weight
1 Technology 21.02%
2 Industrials 13.5%
3 Healthcare 11.15%
4 Financials 9.91%
5 Consumer Discretionary 7.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADXS
301
DELISTED
Advaxis Inc
ADXS
$1.21M 0.1%
12,469
+5,206
+72% +$609K
CRIS icon
302
Curis
CRIS
$9.24M
$1.2M 0.1%
318
+166
+109% +$694K
SYKE
303
DELISTED
SYKES Enterprises Inc
SYKE
$1.19M 0.1%
35,461
+426
+1% +$13.5K
CLDX icon
304
Celldex Therapeutics
CLDX
$3.11B
$1.19M 0.1%
32,001
+16,264
+103% +$719K
GCI
305
DELISTED
Gannett Co., Inc
GCI
$1.18M 0.1%
135,242
+4,314
+3% +$35.6K
BMY icon
306
Bristol-Myers Squibb
BMY
$130B
$1.17M 0.1%
20,997
+5,805
+38% +$316K
NVS icon
307
Novartis
NVS
$295B
$1.17M 0.1%
15,593
+1,691
+12% +$120K
XNCR icon
308
Xencor
XNCR
$1.48B
$1.15M 0.1%
54,436
+19,812
+57% +$444K
GCO icon
309
Genesco
GCO
$444M
$1.15M 0.1%
33,855
+406
+1% +$18.1K
INO icon
310
Inovio Pharmaceuticals
INO
$70.1M
$1.14M 0.09%
12,072
+1,457
+14% +$125K
AZN icon
311
AstraZeneca
AZN
$253B
$1.12M 0.09%
16,477
-16
-0.1% -$1.04K
MGNX icon
312
MacroGenics
MGNX
$249M
$1.11M 0.09%
63,292
+18,309
+41% +$349K
ADAP
313
DELISTED
Adaptimmune Therapeutics
ADAP
$1.09M 0.09%
243,535
+10,894
+5% +$56.9K
BLUE
314
DELISTED
bluebird bio
BLUE
$1.07M 0.09%
786
-176
-18% -$212K
SPTN
315
DELISTED
SpartanNash
SPTN
$1.01M 0.08%
38,754
+466
+1% +$15.3K
DO
316
DELISTED
Diamond Offshore Drilling
DO
$1M 0.08%
92,648
+1,116
+1% +$14.8K
ICLR icon
317
Icon
ICLR
$12.7B
$989K 0.08%
10,111
+266
+3% +$23.5K
JNCE
318
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$964K 0.08%
+68,692
New +$1.47M
MSFT icon
319
Microsoft
MSFT
$3.64T
$928K 0.08%
13,458
-7,318
-35% -$502K
FLOW
320
DELISTED
SPX FLOW, Inc.
FLOW
$926K 0.08%
25,100
+302
+1% +$11.2K
AXE
321
DELISTED
Anixter International Inc
AXE
$920K 0.08%
11,763
+283
+2% +$22.1K
LDOS icon
322
Leidos
LDOS
$16.3B
$912K 0.08%
17,646
+5,870
+50% +$313K
SPG icon
323
Simon Property Group
SPG
$72.8B
$868K 0.07%
5,365
+386
+8% +$62.8K
DXC icon
324
DXC Technology
DXC
$1.77B
$853K 0.07%
+12,855
New +$853K
EXPR
325
DELISTED
Express, Inc.
EXPR
$844K 0.07%
6,252
+75
+1% +$11.6K
11 12
13
14 15

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
WI
Winder Investment Singapore $4.4B AUM 8.87% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return

Vident Investment Advisory's Q2 2017 Portfolio in Review

As of Q2 2017, Vident Investment Advisory held 464 positions worth $1.21B, up 20% from $1.01B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Vident Investment Advisory deployed $179M of net new capital in Q2 2017, opening 45 new positions and adding to 341 existing holdings. Its largest new stake was PTC: 137,032 shares worth $7.55M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 17% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $16.6M trimmed.

  • Vident Investment Advisory's largest Q2 2017 buy was PTC: 137,032 shares worth $7.55M.
  • Vident Investment Advisory added most to Zebra Technologies in Q2 2017, an estimated $8.61M increase.
  • Vident Investment Advisory's biggest Q2 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $16.6M.
  • Vident Investment Advisory fully exited Elbit Systems in Q2 2017, selling an estimated $4.36M.
  • Vident Investment Advisory's ten largest holdings make up 15% of its $1.21B portfolio in Q2 2017.
  • Vident Investment Advisory opened 45 new positions and closed 26 in Q2 2017.
  • Vident Investment Advisory's portfolio value rose 20% quarter-over-quarter to $1.21B.

Based on Vident Investment Advisory's 13F filing for Q2 2017, filed 11 Aug 2017.